Multi-residue analysis of 90 emerging contaminants in liquid and solid environmental matrices by ultra-high-performance liquid chromatography tandem mass spectrometry  by Petrie, Bruce et al.
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Reported  herein  is  new  analytical  methodology  for the  determination  of  90  emerging  contaminants  (ECs)
in  liquid  environmental  matrices  (crude  wastewater,  ﬁnal  efﬂuent  and  river  water).  The  application  of
a  novel  buffer,  ammonium  ﬂuoride  improved  signal  response  for several  ECs  determined  in  negative
ionisation  mode.  Most  notably  the  sensitivity  of steroid  estrogens  was improved  by  4–5 times  in envi-
ronmental  extracts.  Method  recoveries  ranged  from  40 to 152%  in all  matrices  and  method  quantitation
limits  (MQLs)  achieved  were  <1 ng L−1 for  numerous  ECs.  Development  of a microwave  assisted  extraction
(MAE)  protocol  as  an  additional  sample  extraction  step  for solid  matrices  enabled  63  ECs  to  be  simultane-
ously  analysed  in  digested  sludge.  To  the  authors  knowledge  this  is considerably  more  than  any  previously
reported  MAE  method.  Here,  MQLs  ranged  from  0.1–24.1  ng g−1 dry weight.  The  application  of  MAE  offers
several  advantages  over  pressurized  liquid  extraction  including  faster  sample  preparation,  lower  solventludge
ass spectrometry
icrowave assisted extraction
requirements,  and  the  ability  to  perform  several  extractions  simultaneously  as well as  lower  purchas-
ing  and  running  costs.  To demonstrate  the  method’s  sensitivity,  application  to  environmental  samples
revealed  68  and  40  ECs to be  above  their  respective  MQL  in liquid  environmental  samples  and  digested
sludge,  respectively.  To  date,  this  is  the  most  comprehensive  multi-residue  analytical  method  reported
in  the literature  for the  determination  of ECs  in  both  liquid  and  solid  environmental  matrices.
©  2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Municipal derived ECs (personal care products, pharmaceuticals
nd illicit drugs) are widely known to be present in wastewaters,
urface waters and amended agricultural soils [1]. Due to their
harmacological properties, they pose a potential threat to the ecol-
gy of the receiving environment. However, at present ECs are not
egulated by environmental legislation. Current EU legislation is
xpected to be broadened to include ECs as in 2012 diclofenac,
7-estradiol (E2) and 17-ethinylestradiol (EE2) were proposed
s priority hazardous substances [2]. Proposed legislative targets
or consent were 100, 0.4 and 0.035 ng L−1, respectively [2]. These
ery low limits underline the threat posed by this family of envi-
onmental pollutants. For example, proposed legislative targets for
he steroid estrogens are below 1 ng L−1 as they are endocrine dis-
upting chemicals which can exert adverse health effects on the
∗ Corresponding author.
E-mail address: b.kasprzyk-hordern@bath.ac.uk (B. Kasprzyk-Hordern).
ttp://dx.doi.org/10.1016/j.chroma.2015.12.036
021-9673/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
sexual characteristics of ﬁsh [1]. Furthermore, several antibiotics
(erythromycin, clarithromycin, azithromycin) have been recom-
mended for inclusion in the ﬁrst watch list under the Environmental
Quality Standards Directive (2008/105/EC) [3]. Determining envi-
ronmental risk and developing accurate legislation relies on robust
monitoring data-sets for ECs. These are currently lacking and rely
on the application of validated analytical methodologies. Analytical
methods report the use of gas chromatography-mass spectrometry
[4] and more popularly liquid chromatography-mass spectrometry
(LC–MS) [4–8] due to more straight forward sample preparation
requirements for polar chemicals (i.e., no derivatization needed).
The preparation of liquid environmental samples for LC–MS
analysis typically involves ﬁltration to remove particulates and
off-line [6,7] or on-line [5,8] solid phase extraction (SPE). This pre-
concentration step is used to ensure adequate sensitivity for MS
detection [9]. On the other hand, large volume direct injection can
be applied to avoid the use of SPE [10]. This can be suitable where
the MS  detector is sufﬁciently sensitive to monitor ECs at back-
ground concentrations (i.e., ng L−1). For analysis, ultra-performance
liquid chromatography (UPLC) is preferred over conventional LC
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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s the separation method. UPLC provides a more efﬁcient sta-
ionary phase through the reduction in particle size. This results
n higher sensitivity, reduced run times and lower solvent con-
umption [4]. In terms of mechanism of separation, reversed phase
hromatography is most popular as it can successfully separate
 broad range of ECs [4,6]. However, for very polar ECs such as
etformin hydrophilic interaction liquid chromatography (HILIC)
ay  be needed [11]. This approach will require a different sample
iluent and therefore additional samples need to be prepared. For
etection, tandem mass spectrometry (MS/MS) and more speciﬁ-
ally triple quadrupoles are chosen for quantitative environmental
nalysis due to their high sensitivity and selectivity [4].
In the literature, there is a lack of multi-residue methods for the
etermination of ECs in solid matrices. Extraction techniques report
he use of ultra-sonic solvent extraction [12,13], MAE [13–17]
nd pressurized liquid extraction (PLE) [13,18–20]. A compari-
on of these methods for the extraction of quinolone antibiotics
rom sewage sludge revealed no signiﬁcant difference in extrac-
ion efﬁciency between the three techniques [13]. However, MAE
ffers several advantages over PLE such as lower solvent consump-
ions, shorter extraction times and the ability to extract several
amples simultaneously [16]. MAE  relies on microwave energy
o heat the sample/solvent mixture for extraction of ECs [21].
ethods in the literature have reported the successful extraction
f quinolone antibiotics [13], benzophenone derived compounds
16], endocrine disruptors (bisphenol A–BPA, E2, EE2, estriol,
onylphenol, octylphenol and their corresponding ethoxylates)
15], triclosan [14] and some pharmaceuticals and illicit drugs [17].
ollowing extraction, extracts are typically diluted in water to <5%
rganic content and treated as a liquid sample (i.e., subject to SPE
nd analysed by LC–MS/MS).
To date, there have been several shortcomings of previously
eported methods for the determination of ECs in environmental
atrices. These include requiring more than one SPE cartridge for
xtraction and/or requiring more than one sample diluent (e.g.,
or metformin) to encompass a broad range of ECs [22–24], mon-
toring for a limited number of ECs (i.e., <25 and in some cases
ithout metabolites) [5,24–26], validated and applied in less com-
lex environmental matrices only (e.g., ﬁnal efﬂuent and river
ater) [5,8,25] and failure to include analysis of solid matrices
5,7,8,25,26]. To address these shortcomings, the objectives of this
ork were to develop a multi-residue analytical methodology
hich was:
(i) Suitable for the determination of a variety of ECs and their
metabolites exhibiting a range of chemistries and therefore
expectant fate behaviours in environmental matrices.
(ii) Straight forward in its application by utilising a single SPE car-
tridge per analysis (i.e., only one sample diluent required).
iii) Robust in its application across a variety of environmental
matrices of differing complexity (wastewater, river water and
sludge).
iv) Applicable for the analysis of ECs in both liquid and solid envi-
ronmental matrices.
This was achieved by developing off-line SPE (liquid samples)
nd MAE  (solid samples) sample preparation techniques and UPLC-
S/MS  methodology. A total of 90 ECs were included in the method
rom a broad range of chemical classes (UV ﬁlters, parabens,
lasticizers, steroid estrogens, antibacterials/antibiotics, hyper-
ension drugs, non-steroidal anti-inﬂammatory drugs (NSAIDs),
ipid regulators, anti-histamines, drugs for diabetes, cough sup-
ressants, beta-blockers, H2 receptor agonists, drug precursors,
nti-cancer drugs, anaesthetics, anti-depressants, anti-epileptics,. A 1431 (2016) 64–78 65
calcium channel blockers, hypnotics, anti-psychotics, veterinary,
human indicators, analgesics, stimulants, opioids and metabolites).
2. Materials and methods
2.1. Materials
A total of 90 ECs (personal care products, pharmaceuticals and
illicit drugs) were selected for method development. Selection was
based upon reference to existing and proposed EU legislation, UK
prescription data, metabolism and excretion from the human body,
known environmental occurrence, persistence during wastewater
treatment and toxicity to aquatic organisms. Chemical names and
properties of selected ECs are detailed in Table S1.
The internal standards acetaminophen-D4, ibuprofen-
D3, bisphenol A-D16, carbamazepine-13C6, ketoprofen-D3,
naproxen-D3, sertraline-D3, tamoxifen 13C2 15N, propranolol-D7,
atenolol-D5 and metformin (dimethyl-D6) were purchased
from Sigma–Aldrich (Gillingham, UK). Bezaﬁbrate-D6 was
obtained from QMX  laboratories (Thaxted, UK). Methylparaben-
13C, amphetamine-D5, methamphetamine-D5, MDMA-D5,
MDA-D5, heroin-D9, codeine-D6, ketamine-D4, cocaine-D3,
benzoylecgonine-D8, EDDP-D3, morphine-D3, cotinine-D3,
cocaethylene-D8, temazepam-D5, 1S,2R-(+) ephedrine-D3,
mephedrone-D3, methadone-D9, norketamine-D4, estrone
(2,4,16,16-D4), estradiol (2,4,16,16-D4) and quetiapine-D8 hemi-
fumurate were purchased from LGC standards (Middlesex, UK).
Citalopram-D6, metoprolol-D7, ﬂuoxetine-D5 and mirtazapine-D3
were obtained from TRC (Toronto, Canada). All standards were
purchased as 0.1 or 1.0 mg  mL−1 solutions or in powder form.
Those chemicals in powder form were prepared at a concentration
of 1 mg  mL−1 in the recommended solvent and stored in the dark
at –20 ◦C. Stock solutions of antibiotics were prepared monthly.
Methanol (MeOH) and toluene was HPLC grade and pur-
chased from Sigma–Aldrich. Water (H2O) was of 18.2 M quality
(Elga, Marlow, UK). All glassware was  deactivated using 5%
dimethylchlorosilane (DMDCS) in toluene (Sigma–Aldrich) to mit-
igate the loss of basic chemicals onto −OH sites present on
glass surfaces. This consisted of rinsing once with DMDCS, twice
with toluene and three times with MeOH.  A range of mobile
phase buffers were tested during method development including
ammonium acetate (NH4OAc), ammonium formate, ammonium
hydroxide (NH4OH, 30%) and ammonium ﬂuoride (NH4F) obtained
from either Sigma-Aldrich or Fisher Scientiﬁc (Loughborough, UK).
Formic acid (>95%, HCOOH) and acetic acid (1.0 M,  CH3COOH) were
purchased from Sigma–Aldrich. Oasis HLB, MCX  and MAX  (60 mg,
3 mL)  SPE cartridges were purchased from Waters (Manchester,
UK).
To validate the method corresponding grab samples (i.e.,
accounting for hydraulic retention time-HRT) of crude wastewater
and ﬁnal efﬂuent were collected from a trickling ﬁlter wastewa-
ter treatment works (WwTW, population equivalent ∼105,000) in
South–West England. River water from a medium sized river was
also collected upstream of the WwTW discharge point. Samples
were transported to the laboratory on ice and within 15 min  of
collection. Digested sludge was collected from an anaerobic diges-
tion plant in the South-West of England which treats on average,
1800 m3 of waste activated sludge/primary sludge per day. The pro-
cess consists of 6 acid-phase digesters in series and 8 mesophilic
digesters in parallel.2.2. Extraction procedure for liquid samples
Initially, samples were ﬁltered through GF/F ﬁlters (0.7 m)
and adjusted to pH 7.5 ± 0.1. Crude wastewater and ﬁnal efﬂuent
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(Fig. 1. Overview of analytical protocol used to determine target E
50 mL)  and river water (100 mL)  were spiked with 50 ng of all inter-
al standards and loaded onto Oasis HLB cartridges. These were
onditioned using 2 mL  MeOH followed by 2 mL  H2O at a constant
ow rate of 1 mL  min−1. Samples were loaded at 5 mL  min−1 then
ried under vacuum. Elution was performed using 4 mL  MeOH at
 ﬂow rate of 1 mL  min−1. Extracts were then dried under nitrogen
sing a TurboVap evaporator (Caliper, UK, 40 ◦C, N2, <5 psi). This
as then reconstituted in 500 L 80:20 H2O:MeOH and transferred
o polypropylene vials (Waters, Manchester, UK). For samples ana-
ysed by direction injection (i.e., no SPE), 400 L of the ﬁltered
ample was transferred to a vial and spiked with 50 ng of internal
tandards. The volume was then adjusted to 500 L with MeOH to
atch mobile phase starting conditions. A schematic of the extrac-
ion procedure is shown in Fig. 1 .
.3. Extraction of solid matrices by microwave assisted extraction
Digested sludge for extraction was frozen and freeze dried
ScanVac, CoolSafe freeze dryer, Lynge, Denmark). 0.5 g was spiked
ith 50 ng of all internal standards and left for a minimum of 1 h.
xtraction was performed using 25 mL  of 50:50 MeOH:H2O (pH 2)
sing a 800 W MARS 6 microwave (CEM, UK). Samples were heated
o 110 ◦C over 10 min  and then maintained at this temperature for
0 min. Samples were then ﬁltered (0.7 m)  and adjusted to <5%
eOH using H2O (pH 2). Solid phase extraction was  then performed
sing Oasis MCX  cartridges conditioned with 2 mL  MeOH followed
y 2 mL  H2O (pH 2) at 1 mL  min−1. Samples were then loaded at
 mL  min−1 and dried. Analytes were then eluted in separate frac-
ions. Acidic analytes were eluted using 2 mL  0.6% HCOOH in MeOH
fraction 1) and basic analytes in 3 mL  7% NH4OH in MeOH (fractioncrude wastewater, ﬁnal efﬂuent, river water and digested sludge.
2). Dried extracts were then reconstituted separately in 500 L in
80:20 H2O:MeOH and ﬁltered through pre-LCMS 0.2 m PTFE ﬁl-
ters (Whatman, Puradisc) (Fig. 1). During the development process
Oasis HLB, MCX  and MAX  cartridges were trialled. Extraction tem-
peratures of 90, 110 and 130 ◦C and solvent compositions of 90:10,
50:50 and 10:90 H2O:MeOH at pH 2 were also tested.
2.4. Liquid chromatography-mass spectrometry
Chromatography was performed using a Waters Acquity UPLC
system (Waters, Manchester, UK). To maximise sensitivity and
achieve good chromatography for these ECs exhibiting a broad
range of chemistries, two  chromatography methods were devel-
oped.
For acidic compounds, separation was  achieved using
80:20 H2O:MeOH containing 1 mM NH4F (mobile phase A)
and 5:95 H2O:MeOH also containing 1 mM NH4F (mobile phase
B). Starting conditions were 100% A which was maintained for
0.5 min. This was then reduced to 40% A over 2 min  and to 0% A
over 5.5 min. These conditions were maintained for 6 min then
returned to starting conditions. Starting conditions were held
for 8.4 min  to allow re-equilibration. The total run time was
22.5 min. Basic compounds were separated using 5 mM NH4OAc in
80:20 H2O:MeOH containing 0.3% CH3COOH (mobile phase A) and
MeOH (mobile phase B). Starting conditions were 100% A which
were reduced to 10% over 20 min. This was  maintained for 6 min
before returning to starting conditions. Starting conditions were
held for 7.5 min  to allow for re-equilibration. The total run time
was 34 min.
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Both methods used a reversed-phase BEH C18 column (150 × 1.0
m,  1.7 m particle size) (Waters, Manchester, UK) with a 0.2 m,
.1 mm in-line column ﬁlter maintained at 25 ◦C. The mobile phase
ow rate was 0.04 mL  min−1 and an injection volume of 15 L
as used in both methods. The UPLC was coupled to a Xevo TQD
riple Quadrupole Mass Spectrometer (Waters, Manchester, UK),
quipped with an electrospray ionisation source. The determina-
ion of acidic compounds was performed in negative ionisation
ode with a capillary voltage of 3.20 kV. Basic compounds were
etermined in positive mode with a capillary voltage of 3.00 kV. For
oth methods, the source temperature was 150 ◦C and the desolva-
ion temperature was 400 ◦C. The cone gas ﬂow was 100 L h−1and
he desolvation gas ﬂow was 550 L h−1. Nitrogen was  used as the
ebulising and desolvation gas, and argon as the collision gas.
.5. Method performance
Linearity was established by triplicate injection of a 17 point cal-
bration curve ranging in concentration from 0.01–1000 ng mL−1.
nter-day and intra-day precision and accuracy was determined
y triplicate injections of 10, 100 and 500 ng mL−1 within a 24 h
eriod and across three separate days, respectively. Instrumental
etection limits (IDLs) and instrument quantitation limits (IQLs)
ere calculated according to the lowest concentration which gave
 signal to noise ratio of ≥3 and ≥10 respectively. Recovery of tar-
et chemicals was determined by spiking crude wastewater and
nal efﬂuent at a concentration of 100 and 1000 ng L−1. For river
ater, concentrations of 50 and 500 ng L−1 were selected. For those
hemicals determined by direct injection, concentrations of 10 and
00 g L−1 were used. In digested sludge, recovery of analytes was
ssessed at spike concentrations of 50 and 100 ng g−1.
. Results and discussion
.1. Liquid chromatography-tandem mass spectrometry
In order to optimise chromatographic and mass spectrometry
erformance for acidic and basic compounds, analysis was sepa-
ated into two different chromatographic methods (Fig. 2). Both
ethods utilised a reversed-phase BEH C18 column (150 × 1.0 mm,
.7 m particle size) maintained at 25 ◦C with an injection vol-
me  of 15 L. This column has a smaller than typical particle
ize and internal diameter which results in low mobile phase
onsumptions and very good sensitivity [6,18]. To avoid further
ample preparation requirements it was ensured that the same
econstitution diluent (80:20 H2O:MeOH) could be used for both
ethods. For the determination of acidic compounds including
SAIDs, steroid estrogens, parabens, some benzophenones and
ther personal care products a number of mobile phase addi-
ives were tested (see Section 2.1.). A novel buffer, NH4F was
ound to provide excellent chromatographic separations and peak
hapes whilst offering improved signal intensity by up to 5 times
n environmental extracts (Fig. 3). A previous study found signal
ntensities of indomethacin, butylparaben, 11-nor-9-carboxy-9-
etrahydrocannabinol, propylparaben, tetrahydrocannabinol and
riclocarban were all improved by ≥5 times when using NH4F
ver ammonium formate [27]. Increased deprotonation here may
e a result of the strong basicity of the ﬂuoride anion in the gas
hase [28]. It was selected for further method development as
he improved signal response was most notable for the steroid
strogens estrone (E1), E2 and EE2. This is signiﬁcant as these
ompounds are often found in environmental waters at concen-
rations <10 ng L−1 [1]. Furthermore, this enhanced response could
e exploited by dedicated methods aimed at monitoring steroid
strogens (E2 and EE2) at their proposed legislative targets of 0.4. A 1431 (2016) 64–78 67
and 0.035 ng L−1, respectively. These limits are currently below the
detection capabilities of recently reported methodologies which
use a conventional mobile phase containing NH4OH [24,29].
Basic compounds were separated using a MeOH:H2O gradient
containing 5 mM NH4OAc and 3 mM CH3COOH (pH 4.7) and deter-
mined in electro-spray ionisation (ESI)+ mode. These conditions
were vital for achieving good separation and peak shape, particu-
larly for those very polar ECs such as metformin when using a C18
column. Although advantageous for improved response for com-
pounds such as iopromide and methotrexate, any further reduction
of pH resulted in a loss of any chromatographic retention and
peak shape of the more polar ECs. Therefore, the development
of multi-residue methods do result in trade-offs to give the best
overall performance. The addition of NH4OAc  was  important to
improve ESI performance (speciﬁcally for azithromycin), and to
achieve reproducible retention times when analysing environmen-
tal extracts. A concentration of 5 mM was found to be the maximum
concentration which did not negatively affect peak shape and sep-
aration of those early eluting compounds (metformin, creatinine
etc). These conditions avoided the need for a separate method for
very polar chemicals (e.g., HILIC [11]). This would have resulted in
additional sample preparation as different sample diluents would
be needed. A full gradient was  applied which gave good separa-
tion of target ECs with retention times ranging from 2.7 (creatinine,
log Kow 1.7) to 22.4 min  (tamoxifen, log Kow 6.3) (Table S2, Fig. 2).
Tramadol (Peak 60 Fig. 2) was  a co-eluting peak (with desmethyl-
venlafaxine) and as a chromatographic resolution of 1.5 could not
be achieved, quantitation for this compound is only considered
semi-quantitative.
Optimised MS/MS  parameters for 128 chemicals (90 com-
pounds, 38 internal standards) are compiled in Table S2. Of the
chemicals studied, 22 (plus 8 internal standards) were found to
give a higher response in ESI- mode. In ESI+, the remaining 68 (plus
30 internal standards) chemicals were more sensitive. In all cases,
[M H]− for ESI-and [M + H]+ for ESI + were selected as the molecu-
lar ion. Two MRM  transitions were monitored for each compound
(where possible) for quantiﬁcation and conﬁrmation purposes. For
the labelled internal standards, one MRM  transition was monitored
as these will not be found in the environment. Also, due to poor frag-
mentation, only one transition could be monitored for ketoprofen,
diclofenac, ibuprofen, 1,7 dimethylxanthine and norﬂuoxetine. As
these ECs could not satisfy EU guidelines (i.e., two  MRM  transitions)
[30], their analysis can only be considered semi-quantitative. Other
quality criteria used to ensure the quality of data included standard
tolerances of ion ratio and chromatographic retention time [30].
Data acquisition was  performed using time windows of ∼4 min.
This ensured mass spectrometry performance (i.e., number of data
points acquired across a peak) was  not compromised when includ-
ing a high number of chemicals into a single method. The minimum
number of data points across a single peak was 12 where the great-
est number of acquisitions were taking place.
3.2. Instrument performance
Instrument performance was  determined by establishing lin-
ear response, intra- and inter-day precision and accuracy, and
sensitivity (IDLs and IQLs). Mean correlation coefﬁcients (r2) of
the calibration curves were generally ≥0.997 for the concentra-
tion range studied (0–500 or 0–1,000 ng mL−1 dependant on the
concentration of the stock solution purchased) (Table 1). How-
ever, triclosan, benzoylecgonine and mirtazapine did not exhibit
acceptable linearity (i.e., r2 ≥ 0.997) over the entire concentration
range tested. These chemicals were divided into two overlapping
concentration ranges to achieve r2 of ≥0.997. To demonstrate, ben-
zoylecgonine was linear over the concentration ranges 0.05–100
68 B. Petrie et al. / J. Chromatogr. A 1431 (2016) 64–78
Fig. 2. UPLC–MS/MS chromatograms (2–23 min) of ECs extracted from crude wastewater spiked at 1000 ng L−1and analysed under ESI - (A) and ESI+ (B) mobile phase
conditions. Note: see Table 1 for chemical identities.
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Fig. 3. Improvement in signal response using NH4F over NH4OH for the determination of ECs in ESI-mode spiked at 1000 ng L−1 in crude wastewater and subject to SPE
(ordered by retention time).
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Table 1
Instrumental performance data for target ECs in diluent (ordered by retention time).
Chemical No. Linearity Intra-day instrument performanceb Inter-day instrument performanceb IDLS/N(ng mL-1) IQLS/N(ng mL-1)
Range (ng mL-1) r2 Precision (%) Accuracy (%) Precision (%) Accuracy (%)
Chemicals determined in ESI - mode
4-Benzophenone 1 1.01–500 0.997 2.3 103.0 3.8 105.1 0.31 1.01
Sulfasalazine 2 0.90–1,000 0.999 3.9 105.2 2.4 104.7 0.27 0.90
Methylparaben 3 0.06–1,000 0.998 1.1 93.3 6.0 97.4 0.01 0.06
Valsartan 4 1.12–1,000 0.998 1.9 115.8 3.5 118.6 0.34 1.12
2-benzophenone 5 0.05–600 0.997 1.1 99.6 4.2 97.6 0.01 0.05
Bezaﬁbrate 6 0.10–1,000 0.998 2.3 97.8 2.8 97.9 0.03 0.10
Ketoprofen 7 0.54–1,000 0.998 2.2 99.9 2.6 99.4 0.11 0.54
Naproxen 8 0.49–1,000 0.998 1.5 97.7 2.5 98.3 0.10 0.49
Ethylparaben 9 0.11–600 0.997 2.6 112.3 2.1 113.1 0.03 0.11
Fexofenadine 10 0.09–1,000 0.998 2.1 106.3 6.5 104.6 0.03 0.09
Irbesartan 11 0.50–600 0.998 2.6 96.9 4.1 98.3 0.10 0.50
Diclofenac 12 0.10–600 0.997 7.9 89.6 4.5 91.8 0.03 0.10
Bisphenol A 13 0.10–600 0.997 2.4 103.6 1.3 104.6 0.03 0.10
Propylparaben 14 0.12–400 0.997 5.7 96.4 4.3 98.4 0.04 0.12
Atorvastatin 15 0.05–500 0.997 2.6 98.0 3.5 100.9 0.01 0.05
1-Benzophenone 16 0.06–600 0.996 2.3 106.8 3.3 106.7 0.01 0.06
EE2  17 0.48–1,000 0.997 2.6 94.6 3.3 93.2 0.10 0.48
Ibuprofen 18 0.05–1,000 0.998 2.4 93.7 2.3 94.2 0.01 0.05
E2  19 0.47–1,000 0.997 3.1 96.6 2.6 96.3 0.09 0.47
E1  20 0.49–1,000 0.998 1.8 96.9 2.1 98.6 0.10 0.49
Butylparaben 21 0.06–600 0.997 5.0 97.1 3.6 100.3 0.01 0.06
Triclosana 22 1.13–200100–1,000 0.9970.998 9.4 69.6 6.5 71.4 0.34 1.13
Chemicals determined in ESI + mode
Creatinine 23 1.00–1,000 0.999 2.8 100.1 1.4 100.5 0.30 1.00
Metformin 24 0.43–1,000 0.998 1.3 97.0 1.5 96.3 0.09 0.43
Dihydromorphine 25 0.05–500 0.997 2.7 108.5 4.4 106.0 0.01 0.05
Nicotine 26 1.00–500 0.998 2.4 98.4 1.2 98.3 0.30 1.00
Normorphine 27 1.00–500 0.999 2.2 99.8 1.5 100.9 0.30 1.00
Anhydroecgonine methylester 28 0.50–500 0.999 2.4 98.7 2.3 101.1 0.10 0.50
Morphine 29 1.00–500 0.998 2.5 97.5 2.9 99.1 0.30 1.00
Pholcodine 30 1.14–500 0.999 3.3 99.2 4.7 99.5 0.35 1.14
Atenolol 31 0.10–500 0.999 2.3 96.8 2.1 95.3 0.03 0.10
Ranitidine 32 5.17–500 0.998 9.7 97.4 2.5 100.1 1.03 5.17
Iopromide 33 5.79–1,000 0.997 12.0 105.4 5.0 101.2 1.16 5.79
Acetaminophen 34 0.54–1,000 0.998 2.6 99.0 1.6 97.4 0.11 0.54
Cimetidine 35 0.52–500 0.999 9.0 99.3 4.2 104.1 0.10 0.52
Dihydrocodeine 36 0.10–500 0.999 2.1 94.6 1.6 94.2 0.03 0.10
Codeine 37 0.50–500 0.997 4.0 95.1 2.0 93.5 0.10 0.50
Norephedrine 38 0.50–1,000 0.999 5.1 95.2 4.3 96.3 0.01 0.50
Norcodeine 39 1.00–500 0.998 4.8 98.6 2.8 98.5 0.30 1.00
1,7  dimethylxanthine 40 1.00–500 0.999 9.9 94.9 6.0 94.3 0.30 1.00
Lisinopril 41 0.93–400 0.995 7.2 95.2 2.2 97.2 0.09 0.93
Ephedrine/pseudoephedrine 42 0.10–500 0.997 3.4 97.3 4.1 94.0 0.03 0.10
Cotinine 43 0.05–1,000 0.999 1.5 98.8 1.5 98.4 0.01 0.05
6-Acetylmorphine 44 0.10–500 0.997 5.1 100.1 6.1 95.3 0.03 0.10
Azathioprine 45 0.10–500 0.999 13.9 97.4 7.6 97.5 0.03 0.10
Methotrexate 46 0.92–500 0.997 4.1 112.2 8.7 108.0 0.28 0.92
Caffeine  47 0.50–500 0.999 2.8 100.4 1.7 99.6 0.10 0.50
O-desmethyltramadol 48 1.00–400 0.997 4.9 98.5 3.3 95.3 0.01 1.00
Amphetamine 49 0.10–500 0.999 1.6 100.7 4.4 100.8 0.03 0.10
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Table 1 (Continued)
Chemical No. Linearity Intra-day instrument performanceb Inter-day instrument performanceb IDLS/N(ng mL-1) IQLS/N(ng mL-1)
Range (ng mL-1) r2 Precision (%) Accuracy (%) Precision (%) Accuracy (%)
Trimethoprim 50 0.10–500 0.998 2.2 99.5 3.0 96.9 0.03 0.10
Methamphetamine 51 0.10–500 0.999 1.3 101.1 2.2 101.0 0.03 0.10
MDA  52 0.10–1,000 0.998 0.7 100.0 1.1 98.4 0.03 0.10
MDMA  53 0.05–1,000 0.999 1.7 99.8 1.3 99.2 0.01 0.05
Sulfamethoxazole 54 0.10–1,000 0.999 2.4 96.0 3.5 95.1 0.03 0.10
Benzoylecgoninea 55 0.05–10050–500 0.9980.999 0.9 103.2 2.4 103.4 0.01 0.05
Mephedrone 56 0.05–500 0.998 2.9 85.7 1.8 87.1 0.01 0.05
Ketamine 57 0.05–500 0.998 1.3 93.6 1.8 92.5 0.01 0.05
Desmethylvenlafaxine 58 0.10–500 0.998 2.1 102.3 2.8 101.3 0.03 0.10
Heroin  59 0.50–500 0.999 1.8 99.3 1.9 98.2 0.10 0.50
Tramadol 60 1.00–500 0.999 1.9 98.4 1.6 100.1 0.01 1.00
Norketamine 61 0.10–500 0.999 3.2 94.0 1.8 94.1 0.03 0.10
Metoprolol 62 0.05–500 0.999 2.0 96.1 1.3 96.8 0.01 0.05
Cocaine  63 0.05–500 0.999 1.5 99.0 2.2 97.2 0.01 0.05
N-desmethyltramadol 64 0.50–500 0.998 2.2 94.4 2.5 92.5 0.01 0.50
MDPV  65 0.05–500 0.999 0.7 101.4 2.2 99.6 0.01 0.05
Ifosfamide 66 0.05–500 0.999 2.7 95.3 2.4 93.6 0.01 0.05
Cocaethylene 67 0.05–500 0.999 1.7 94.7 2.8 95.1 0.01 0.05
Carbamazepine10,11-epoxide 68 0.10–1,000 0.997 2.1 89.9 1.6 88.9 0.03 0.10
10,11-Dihydro-10-hydroxycarbamazepine 69 0.50–1,000 0.997 5.6 93.8 2.8 92.2 0.05 0.50
Mirtazapinea 70 0.05–10050–500 0.9990.997 2.7 97.6 3.4 94.8 0.01 0.05
Azithromycin 71 0.11–500 0.998 2.1 98.5 3.8 95.0 0.03 0.11
Venlafaxine 72 0.04–500 0.998 1.7 90.5 2.5 91.2 0.01 0.04
EDDP  73 0.05–500 0.999 1.1 96.4 1.2 96.5 0.01 0.05
Citalopram 74 0.50–1,000 0.999 2.6 101.8 0.7 101.2 0.05 0.50
Propranolol 75 0.09–500 0.999 1.0 106.2 2.0 105.4 0.03 0.09
Desmethylcitalopram 76 0.05–500 0.998 3.0 103.4 1.8 103.0 0.01 0.05
Carbamazepine 77 0.05–500 1.000 1.6 92.7 2.0 91.7 0.01 0.05
Diltiazem 78 0.10–500 0.996 2.3 93.6 2.3 92.7 0.01 0.10
Tylosin  79 0.56–500 0.999 4.0 100.2 2.2 99.5 0.11 0.56
Methadone 80 0.05–400 0.998 1.4 100.2 1.5 98.7 0.01 0.05
Gliclazide 81 0.05–500 0.997 2.8 95.3 2.1 93.2 0.01 0.05
Quetiapine 82 0.05–1,000 0.997 1.2 96.4 1.4 95.3 0.01 0.05
Temazepam 83 0.05–500 0.998 1.6 97.9 1.0 97.0 0.01 0.05
Fluoxetine 84 0.05–1,000 0.999 1.8 98.3 1.7 96.8 0.01 0.05
Norﬂuoxetine 85 0.05–500 0.998 3.1 103.1 1.5 102.7 0.01 0.05
Cetirizine 86 0.08–500 0.999 1.3 100.8 1.3 100.5 0.02 0.08
Clarithromycin 87 0.06–500 0.999 2.4 101.8 2.6 99.8 0.01 0.06
Sertraline 88 0.05–500 1.000 1.7 95.7 1.6 95.3 0.01 0.05
3-Benzophenone 89 0.05–400 0.995 4.5 86.8 3.2 84.9 0.01 0.05
Tamoxifen 90 0.03–1,000 0.998 2.4 96.8 4.0 96.0 0.01 0.03
Key: IDL, instrument detection limit; IQL, instrument quantitation limit.
a Two different calibrations used as linear relationship was not established over the complete concentration range.
b Instrument performance was  determined at concentrations of 10, 100 and 500 ng mL.
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Fig. 4. Matrix suppression of target EC response in crude wastewater extracts (ordered by retention time). Compounds marked with * were determined by direct injection
(no  SPE).
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Fig. 5. Absolute and corrected recovery of target ECs in crude wastewater spiked at 100 and 1000 ng L−1, respectively (ordered by retention time). Those marked with * were
determined by direct injection (no SPE).
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Table  2
Method detection limits and method quantitation limits for target ECs in crude wastewater, ﬁnal efﬂuent, river water and digested sludge (ordered by retention time).
Chemical Crude wastewater Final efﬂuent River water Digested sludge
MDL (ng L−1) MQL  (ng L−1) MDL (ng L−1) MQL  (ng L−1) MDL (ng L−1) MQL  (ng L−1) MDL  (ng g−1) MQL  (ng g−1)
Chemicals determined in ESI - mode
4-benzophenone 7.83 25.84 5.78 19.09 2.09 6.90 4.01 13.22
Sulfasalazine 12.55 41.43 9.66 31.87 4.31 14.23 – –
Methylparaben 0.28 1.41 0.19 0.94 0.08 0.40 0.06 0.31
Valsartan 7.24 23.90 6.40 21.12 2.81 9.26 – –
2-benzophenone 0.36 1.82 0.34 1.68 0.16 0.79 0.09 0.44
Bezaﬁbrate 0.64 2.11 0.38 1.25 0.22 0.66 0.18 0.60
Ketoprofen 2.38 11.90 1.60 8.00 0.74 3.72 0.47 2.35
Naproxen 6.29 31.45 1.17 5.85 0.61 3.07 0.60 3.02
Ethylparaben 0.49 1.61 0.46 1.52 0.24 0.79 0.17 0.57
Fexofenadine 0.56 1.85 0.40 1.32 0.21 0.69 – –
Irbesartan 2.50 12.49 1.88 9.38 0.89 4.47 – –
Diclofenac 0.67 2.22 0.44 1.44 0.22 0.73 0.75 2.46
Bisphenol A 0.85 2.79 0.56 1.84 0.26 0.86 0.27 0.88
Propylparaben 0.63 2.08 0.47 1.54 0.25 0.83 0.22 0.72
Atorvastatin 0.17 0.85 0.17 0.84 0.14 0.70 – –
1-Benzophenone 0.23 1.15 0.14 0.71 0.07 0.35 0.14 0.70
EE2  1.83 9.15 1.46 7.32 0.98 4.91 – –
Ibuprofen 0.19 0.93 0.08 0.42 0.06 0.31 0.07 0.36
E2  1.84 9.22 1.41 7.03 0.90 4.48 1.48 7.41
E1  1.96 9.78 1.54 7.69 0.78 3.92 1.68 8.38
Butylparaben 0.24 1.21 0.14 0.71 0.08 0.38 0.10 0.52
Triclosan 4.93 16.27 4.55 15.02 2.93 9.68 – –
Chemicals determined in ESI + mode
Creatinine 945* 3,118* 771* 2,544* 511* 1,686* – –
Metformin 457* 1,509* 163* 460* 156* 515* – –
Dihydromorphine 0.50 2.51 0.32 1.59 0.11 0.55 0.09 0.45
Nicotine 508* 2,296* 5.44 17.95 3.34 11.03 0.66 2.19
Normorphine 9.99 32.96 7.84 25.88 3.54 11.67 1.74 5.75
Anhydroecgonine methylester 2.95 14.76 1.99 9.96 0.93 4.67 – –
Morphine 8.85 29.20 6.34 20.92 2.65 8.75 1.92 6.33
Pholcodine 25.25 83.32 8.02 26.45 2.25 7.42 1.52 5.00
Atenolol 0.71 2.35 0.56 1.84 0.20 0.66 0.10 0.33
Ranitidine 14.76 73.79 22.28 111.39 7.96 39.79 4.81 24.05
Iopromide 24.51 123 14.11 70.56 5.97 29.85 – –
Acetaminophen 138* 1,017* 2.39 11.95 1.20 6.02 2.74 13.72
Cimetidine 5.06 25.32 3.12 15.59 1.60 7.98 – –
Dihydrocodeine 0.88 2.89 0.55 1.83 0.23 0.75 0.11 0.36
Codeine 2.56 12.82 1.46 7.31 0.74 3.71 0.33 1.66
Norephedrine 0.37 18.60 0.35 17.28 0.18 8.82 0.04 1.85
Norcodeine 8.53 28.15 8.32 27.44 2.88 9.52 1.26 4.17
1,7  dimethylxanthine 560* 2,165* 11.40 37.63 3.19 10.53 – –
Lisinopril 3.25 32.54 4.25 42.51 2.17 21.73 0.25 2.47
Ephedrine/pseudoephedrine 1.32 4.36 1.62 5.36 0.60 1.97 0.11 0.35
Cotinine 0.27 1.34 0.21 1.06 0.07 0.35 0.24 1.22
6-Acetylmorphine 0.89 2.95 0.76 2.50 0.28 0.94 – –
Azathioprine 0.41 1.36 0.36 1.20 0.17 0.55 – –
Methotrexate 7.11 23.45 9.04 29.83 6.13 20.24 1.64 5.42
Caffeine 121* 581* 1.11 5.57 0.37 1.83 – –
O-desmethyltramadol 0.31 31.41 0.28 27.79 0.09 8.53 – –
Amphetamine 1.23 4.07 1.11 3.65 0.68 2.23 0.09 0.29
Trimethoprim 0.73 2.41 0.51 1.67 0.26 0.85 0.07 0.22
Methamphetamine 0.95 3.13 0.71 2.35 0.32 1.05 0.09 0.30
MDA  0.99 3.26 1.00 3.30 0.53 1.74 – –
MDMA 0.34 1.70 0.27 1.35 0.10 0.50 0.04 0.18
Sulfamethoxazole 0.72 2.38 0.47 1.56 0.19 0.63 0.12 0.41
Benzoylecgonine 0.21 1.07 0.18 0.91 0.07 0.34 0.03 0.14
Mephedrone 0.55 2.75 0.44 2.19 0.22 1.09 0.06 0.31
Ketamine 0.24 1.20 0.19 0.93 0.07 0.37 0.03 0.17
Desmethylvenlafaxine 0.85 2.79 0.66 2.18 0.24 0.80 0.09 0.29
Heroin 4.18 20.89 3.44 17.21 0.92 4.62 0.56 2.79
Tramadol 0.30 30.03 0.21 21.29 0.08 8.20 0.03 3.26
Norketamine 0.72 2.37 0.56 1.86 0.23 0.76 0.10 0.33
Metoprolol 0.28 1.40 0.19 0.96 0.07 0.35 0.03 0.14
Cocaine 0.46 2.31 0.22 1.11 0.07 0.35 0.03 0.15
N-desmethyltramadol 0.56 27.90 0.30 14.97 0.12 5.92 0.04 2.02
MDPV 0.48 2.41 0.12 0.59 0.04 0.22 0.04 0.20
Ifosfamide 0.31 1.53 0.24 1.22 0.08 0.40 – –
Cocaethylene 1.31 6.54 0.21 1.04 0.07 0.35 0.03 0.17
Carbamazepine10,11-epoxide 0.53 1.76 0.55 1.82 0.16 0.53 – –
10,11-dihydro-10-hydroxycarbamazepine 0.99 9.94 0.84 8.41 0.34 3.37 0.43 4.35
Mirtazapine 0.39 1.94 0.25 1.25 0.09 0.44 0.05 0.27
Azithromycin 0.74 2.45 1.35 4.45 0.70 2.30 – –
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Table 2 (Continued)
Chemical Crude wastewater Final efﬂuent River water Digested sludge
MDL  (ng L−1) MQL  (ng L−1) MDL  (ng L−1) MQL  (ng L−1) MDL  (ng L−1) MQL  (ng L−1) MDL  (ng g−1) MQL  (ng g−1)
Venlafaxine 0.37 1.83 0.24 1.20 0.07 0.37 0.08 0.38
EDDP 0.23 1.13 0.29 1.47 0.21 1.05 0.04 0.20
Citalopram 1.24 12.40 1.41 14.10 0.61 6.08 0.16 1.64
Propranolol 0.68 2.25 0.73 2.41 0.29 0.96 0.13 0.42
Desmethylcitalopram 0.31 1.54 0.36 1.82 0.14 0.69 0.05 0.24
Carbamazepine 0.27 1.37 0.19 0.93 0.08 0.38 0.10 0.48
Diltiazem 0.27 2.68 0.32 3.23 0.11 1.11 – –
Tylosin 3.27 16.34 2.23 11.14 1.28 6.39 – –
Methadone 0.20 1.01 0.21 1.04 0.11 0.54 0.03 0.17
Gliclazide 0.22 1.09 0.16 0.82 0.15 0.77 – –
Quetiapine 0.26 1.32 0.21 1.07 0.10 0.48 0.05 0.26
Temazepam 0.18 0.92 0.14 0.69 0.08 0.38 0.16 0.82
Fluoxetine 0.50 2.52 1.42 7.08 1.14 5.71 0.11 0.53
Norﬂuoxetine 0.42 2.12 1.27 6.35 1.64 8.21 0.14 0.68
Cetirizine 0.52 1.72 0.32 1.06 0.26 0.87 – –
Clarithromycin 0.34 1.69 0.28 1.40 0.18 0.90 – –
Sertraline 0.74 3.72 1.21 6.05 1.61 8.07 0.17 0.86
3-benzophenone 0.37 1.87 0.19 0.97 0.15 0.77 – –
Tamoxifen 0.70 3.50 0.76 3.82 14.52 72.60 2.23 11.14
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Determined by direction injection (i.e., no SPE performed); -Compound was not ex
nd 50–500 ng mL−1 with r2’s of 0.998 and 0.999, respectively
Table 1). For concentrations between 50 and 100 ng mL−1, the
ower calibration range was applied. Both intra-and inter-day pre-
ision showed a deviation of <10% for the majority of chemicals
tudied. Accuracy was typically within the range 90–110% for most
hemicals both within the same day and between different days.
QLs ranged from 30 ng L−1 for tamoxifen to ∼5,000 ng L−1 for rani-
idine and iopromide (Table 1). Such a wide range of IDLs and IQLs is
ypical for multi-residue methods which include a large number of
hemicals of varying chemical properties [7,8]. Nevertheless, these
DLs and IQLs are insufﬁcient to monitor all chemicals at concen-
rations typically found in environmental matrices. To overcome
his, SPE was proposed as a pre-concentration step to allow their
uantitation at indigenous levels.
.3. Sample extraction and matrix effects
For the extraction of ECs from liquid samples a previously
eported methodology by Kasprzyk–Hordern et al [31]. was
pplied. The Oasis HLB SPE sorbent was used as it utilises both
ydrophilic and lipophilic retention mechanisms at neutral pH.
onsequently it is suitable for the simultaneous extraction of a
road range of chemicals and has been widely applied for a large
umber of ECs in various environmental matrices [4,7]. However,
uring the development process it was found that the very polar
ompounds metformin and creatinine were recovered by <1% in
ll matrices studied. Nevertheless, they are commonly observed
n environmental matrices at concentrations >1,000 ng L−1 [6,32].
uch concentrations are sufﬁcient to monitor by direct injection,
ithout the need for SPE. A different sample preparation method
as proposed for these compounds and involved simply ﬁlter-
ng the sample, spiking with internal standards and adjusting to
0% MeOH to avoid chromatography issues such as band broad-
ning (Fig. 1). This avoided the need for a separate SPE protocol
o encompass all compounds studied. Furthermore, this approach
as used to analyse acetaminophen, caffeine, nicotine and 1,7
imethylxanthine in crude wastewater due to their relatively high
oncentrations observed here. Otherwise, extracts would require to
e diluted and re-analysed to ensure they fall within their respec-
ive calibration ranges. Therefore, overall analysis time was  not
ompromised by applying direct injection as well as SPE. A dis-
dvantage of using Oasis HLB SPE is that it is non-selective and
o-extracted matrix can cause signiﬁcant analyte signal suppres-d or failed quality control criteria.
sion when using ESI [4]. To demonstrate, in crude wastewater
matrix suppressions up to 90% (pholcodine) are observed (Fig. 4).
Signal enhancement can also be observed [4], particularly in ESI-
mode. This illustrates the necessity of using internal standards to
correct for these matrix interferences (and any losses during sam-
ple preparation). Absolute and corrected recoveries (accounting for
internal standard losses) are detailed in Fig. 5 and Table S5.
During development of the method for solid matrices, very low
or no recovery was  observed for many compounds determined
in ESI + mode. The very complex nature of extracts from digested
sludge quenched analyte signal during ESI. This was conﬁrmed by
spiking extracts post SPE, demonstrating that non-selective Oasis
HLB SPE was unsuitable for solid extracts (dilution of extracts was
also insufﬁcient for reducing matrix interferences and improving
sensitivity). To overcome this issue, fractionation of acidic/basic
analytes during SPE was  investigated. This involved eluting acidic
and basic fractions into separate SPE vials to reduce matrix interfer-
ences. Oasis MAX  and MCX  were trialled and found to be successful
at reducing matrix suppression signiﬁcantly. The cation-exchange
mixed-mode polymeric sorbent (MCX) was chosen as it provided
the greatest recoveries. For this method, samples were adjusted to
pH 2 to ionise basic compounds prior to SPE [6]. Acidic compounds
were eluted from the cartridge in 2 mL  of 0.6% HCOOH in MeOH
(fraction 1) and basic compounds separately in 3 mL  7% NH4OH in
MeOH (fraction 2), similar to the method reported by Baker and
Kasprzyk-Hordern [6]. Development of the MAE  method involved
investigating the impact of solvent composition and extraction
temperature on analyte recovery. A solvent mixture comprising
50:50 H2O:MeOH (pH 2) and an extraction temperature of 110 ◦C
gave the best recoveries (Fig. S1). These conditions are similar to
other previously reported MAE  methods [14–17]. Extraction at pH
2 was selected as it is beneﬁcial to some compounds such as ben-
zophenones [16] and is the pH required for SPE. The developed
method was suitable for the determination of 63 of the 90 ECs
studied (70%) (Table 2). To our knowledge, this is considerably
more than previously reported MAE  methods [14–17]. The remain-
ing ECs which could not be analysed using the described method
were poorly extracted during MAE  or were not recovered using the
SPE method applied. This includes some ECs identiﬁed in proposed
EU legislation such as azithromycin and clarithromycin. These ECs
would require a different method(s), more targeted towards their
speciﬁc analysis needs. This outlines the difﬁculty of undertaking
multi-residue analysis of such complex solid wastewater matrices.
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Table 3
Quantitative information for target ECs in crude wastewater, ﬁnal efﬂuent, river water and digested sludge (n = 3) (ordered by chemical class).
Chemical class Chemical Crude wastewater(ng L-1) Final efﬂuent (ng L-1) Removala(%) River water(ng L-1) Digested sludge (ng g-1dry weight)
UV ﬁlters Benzophenone-1 145 ± 10.0 <MQL >99 <MQL 86.1 ± 25.8
Benzophenone-2 <MQL <MQL – <MQL <MQL
Benzophenone-3 369 ± 10.1 91.4 ± 5.7 75 65.7 ± 11.3 –
Benzophenone-4 3,298 ±313 3,860 ± 329 −17 207 ± 11.8 <MQL
Parabens Methylparaben 1,196 ± 102 6.4 ± 0.6 99 10.8 ± 2.5 219 ± 81.2
Ethylparaben 357 ± 15.1 6.3 ± 0.6 98 1.8 ± 0.3 <MQL
Propylparaben 722 ± 55.2 5.8 ± 2.6 99 <MQL <MQL
Butylparaben 38.3 ± 2.6 <MQL >98 <MQL <MQL
Plasticizer Bisphenol-A 624 ± 126 205 ± 14.5 67 62.3 ± 17.0 5,800 ± 1,070
Steroid estrogens E1 44.5 ± 3.0 15.8 ± 4.6 64 <MQL 77.2 ± 1.1
E2  <MQL <MQL – <MQL <MQL
EE2  <MQL <MQL – <MQL –
Antibacterials/antibiotics Sulfasalazine <MQL <MQL – <MQL –
Clarithromycin 907 ± 87.6 1,065 ± 121 −17 43.5 ± 7.2 –
Azithromycin 162 ± 17.0 87.2 ± 10.7 46 <MQL –
Trimethoprim 672 ± 23.3 769 ± 65.5 −15 22.0 ± 3.1 21.5 ± 1.7
Sulfamethoxazole 113 ± 14.1 47.5 ± 10.6 58 1.8 ± 0.2 <MQL
Triclosan 1,053 ± 105 199 ± 20.6 81 101 ± 9.2 –
Hypertension Valsartan 322 ± 31.8 273 ± 6.4 15 38.1 ± 2.0 –
Irbesartan 152 ± 16.5 166 ± 8.1 -9 <MQL –
Lisinopril <MQL <MQL – <MQL <MQL
NSAIDs Ketoprofen <MQL <MQL – <MQL <MQL
Ibuprofen 12,907 ± 434 1,290 ± 16.8 90 27.5 ± 3.5 174 ± 4.2
Naproxen 13,660 ± 541 3,516 ± 94.9 74 127 ± 7.8 39.8 ± 8.5
Diclofenac 549 ± 49.1 436 ± 6.2 21 21.5 ± 3.6 23.5 ± 6.4
Acetaminophen 138,164 ± 11,873 1,454 ± 77.8 99 163 ± 2.8 10.3 ± 3.6
Lipid  regulators Bezaﬁbrate 1,540 ± 120 892 ± 16.5 42 42.1 ± 0.8 <MQL
Atorvastatin 188 ± 12.5 60.5 ± 3.5 68 7.0 ± 1.1 –
Antihistamines Fexofenadine 770 ± 55.5 598 ± 7.9 22 63.7 ± 5.7 –
Cetirizine 1,571 ± 182 1,961 ± 147 −25 195 ± 42.1 –
Diabetes Metformin 44,204 ± 900 19,784 ± 257 55 2,318 ±63 –
Gliclazide 34.5 ± 2.8 30.0 ± 0.7 13 <MQL –
Cough  suppressant Pholcodine <MQL <MQL – <MQL 17.3 ± 0.5
Beta-blocker Atenolol  1,689 ± 141 683 ± 148 60 20.1 ± 1.4 26.8 ± 0.4
Metoprolol 37.0 ± 4.9 43.1 ± 7.0 −16 <MQL 1.0 ± 0.1
Propranolol 122 ± 13.4 116 ± 12.0 5 <MQL 192 ± 5.1
H2 receptor agonists Ranitidine 781 ± 78.0 475 ± 6.6 39 <MQL 47.1 ± 3.1
Cimetidine 107 ± 14.1 148 ± 12.3 −38 <MQL –
X-ray  contrast media Iopromide <MQL <MQL – <MQL –
Drug  precursor and
metabolite
Ephedrine/pseudoephedrine 465 ± 17.7 125 ± 4.2 73 <MQL 15.1 ± 6.9
Norephedrineb <MQL <MQL – <MQL <MQL
Anti-cancer Azathioprine <MQL <MQL – <MQL –
Methotrexate <MQL <MQL – <MQL <MQL
Ifosfamide <MQL <MQL – <MQL –
Tamoxifen <MQL <MQL – <MQL <MQL
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Chemical class Chemical Crude wastewater(ng L-1) Final efﬂuent (ng L-1) Removala(%) River water(ng L-1) Digested sludge (ng g-1dry weight)
Anaesthetic and
metabolite
Ketamine <MQL 9.5 ± 0.7 – <MQL 0.3 ± 0.1
Norketamineb <MQL <MQL – <MQL 0.9 ± 0.2
Anti-depressants and
metabolites
Venlafaxine 387 ± 43.1 355 ± 24.0 8 31.1 ± 1.5 37.9 ± 0.2
Desmethylvenlafaxineb 86.3 ± 5.7 87.1 ± 4.1 −1 7.3 ± 1.9 15.5 ± 0.7
Fluoxetine 36.0 ± 11.3 26.5 ± 3.5 26 <MQL 188 ± 24.1
Norﬂuoxetineb 38.5 ± 7.8 30.0 ± 2.8 22 <MQL 124 ± 0.9
Sertraline 74.0 ± 25.4 47.0 ± 5.1 36 <MQL 1,138 ± 35.5
Mirtazapine 60.0 ± 4.2 55.0 ± 2.8 8 <MQL 66.1 ± 0.4
Citalopram 340 ± 31.1 323 ± 11.3 5 <MQL 657 ± 37.8
Desmethylcitalopramb 80.0 ± 9.9 72.5 ± 0.7 9 <MQL 193 ± 12.0
Anti-epileptic and
metabolites
Carbamazepine 650 ± 46.0 316 ± 5.7 51 75.8 ± 12.0 121 ± 5.4
Carbamazepine10,11-epoxideb 36.0 ± 1.4 42.0 ± 11.3 −17 <MQL –
10,11-Dihydro-10-hydroxycarbamazepineb 18.5 ± 3.5 103 ± 10.3 −457 <MQL <MQL
Calcium  channel blocker Diltiazem 190 ± 5.0 41.8 ± 7.0 78 <MQL –
Hypnotic Temazepam 57.5 ± 3.5 121 ± 5.7 −110 <MQL <MQL
Anti-psychotic Quetiapine 80.0 ± 7.1 2.0 ± 0.4 98 <MQL 23.3 ± 4.5
Veterinary Tylosin <MQL <MQL – <MQL –
Human  indicators and
metabolites
Creatinineb 83,125 ± 9,461 <MQL 94 <MQL –
Nicotine 7,750 ± 937 148 ± 9.4 98 33.5 ± 5.1 139 ± 26.4
Caffeine 74,813 ± 5,329 5,991 ± 157 92 247 ± 10.5 –
Cotinineb 1,972 ± 285 360 ± 28.3 82 29.8 ± 2.1 47.6 ± 10.6
1,7  dimethylxantineb 146,500 ± 1,687 6,873 ± 367 95 345 ± 74.9 –
Analgaesics and
metabolites
Morphine 1,093 ± 78.4 202 ± 19.0 82 <MQL 277 ± 30.5
Dihydromorphineb <MQL <MQL – <MQL 28.5 ± 4.5
Normorphineb 86.0 ± 2.8 <MQL >70 <MQL 25.5 ± 3.3
Methadone 59.5 ± 7.0 28.0 ± 1.4 53 <MQL 24.6 ± 0.4
EDDPb 106 ± 9.8 87.5 ± 6.4 17 <MQL 118 ± 1.6
Codeine 1,290 ± 116.0 923 ± 21.2 28 32.0 ± 1.4 67.7 ± 8.6
Norcodeineb 120 ± 15.5 84.5 ± 7.0 30 <MQL <MQL
Dihydrocodeineb 155 ± 14.8 232 ± 11.3 −50 12.5 ± 2.8 24.2 ± 0.2
Tramadol 897 ± 166 930 ± 84.1 −4 131 ± 21.2 21.2 ± 0.9
N-desmethyltramadolb 209 ± 4.2 341 ± 4.9 −63 42.5 ± 7.1 8.7 ± 0.2
O-desmethyltramadolb 978 ± 28.3 671 ± 33.5 31 95.0 ± 7.1 –
Stimulants and
metabolites
Amphetamine 288 ± 17 67.0 ± 1.4 77 <MQL 7.5 ± 0.2
Methamphetamine <MQL <MQL – <MQL <MQL
MDMA  43.0 ± 5.8 56.5 ± 7.1 −31 <MQL 10.3 ± 0.6
MDAb <MQL 16.0 ± 4.2 <−220 <MQL –
Cocaine 430 ± 39.6 72.5 ± 0.7 83 <MQL 3.1 ± 0.3
Benzoylecgonineb 1,247 ± 70.7 389 ± 35.3 69 10.8 ± 2.1 <MQL
Anhydroecgonine methylesterb <MQL <MQL – <MQL –
Cocaethyleneb <MQL <MQL – <MQL <MQL
Mephedrone 27.5 ± 2.1 <MQL >92 <MQL <MQL
MDPV  <MQL <MQL – <MQL <MQL
Opioid  and metabolite Heroin <MQL <MQL – <MQL <MQL
6-Acetylmorphineb <MQL <MQL – <MQL –
Key: MQL, method quantitation limit.
a Removal (%) = (CW − FE)/CW × 100 where CW is the crude wastewater concentration (ng L1) and FE is the ﬁnal efﬂuent concentration (ng L1).
b Metabolite.
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ecoveries from digested sludge ranged from 49 to 180% with the
ajority of compounds exhibiting recoveries in the range 90-110%
Table S5). In contrast to liquid extracts, no signal enhancement was
bserved for any of the ECs studied. This is owed to the increased
omplexity of digested sludge extracts. Matrix suppressions ranged
rom 27.5% for dihydromorphine to 88.6% for naproxen (Table S6).
.4. Method sensitivity
The ﬁnal method achieved MDLs <0.1 ng L−1 for numerous ECs
n liquid environmental samples (Table 2). MQLs achieved were
1 ng L−1 for several compounds up to a maximum of 171 ng L−1
or ranitidine in wastewater samples where SPE was applied
Table 2). This range of MQLs is typical for multi-residue meth-
ds [7,8]. The MQLs of E1 and E2 in wastewaters were in the range
.03–13.7 ng L−1 and suitable for the concentrations expected to
e encountered in municipal wastewaters [1,24]. This is advanta-
eous as these compounds have not previously been quantiﬁable in
ulti-residue methods (>50 compounds) which extract relatively
ow sample volumes (50 mL). The improvement in sensitivity (and
QL) was attributable to the application of NH4F as a negative ion
uffer. However, the very low concentrations anticipated for EE2
<1 ng L−1 [24]) continues to be a challenge and are below the MQL
or the methodology reported here. For those compounds analysed
y direct injection (metformin, creatinine, acetaminophen, 1,7
imethylxantine, caffeine and nicotine), MQLs in crude wastewater
anged from 700 ng L−1 for caffeine to 13,657 ng L−1 for creatinine
Table 2). Despite being signiﬁcantly higher than those reported for
ompounds where SPE was applied, these MQLs were sufﬁcient for
heir determination as these ECs are found in comparatively higher
oncentrations (Table 3). In digested sludge, MDLs ranged from 0.03
o 4.81 ng g−1 and MQLs from 0.14 to 24.05 ng g−1 (Table 2). Despite
hese being similar to previously reported PLE methods [18], the
AE  reported here required lower solvent volumes for extraction.
AE  systems are also cheaper to purchase and run than PLE. Fur-
hermore, sample preparation for MAE  is more straightforward and
t offers the ability to perform several extractions simultaneously.
.5. Application to environmental matrices
The new multi-residue analytical method was applied to
etermine the concentration of ECs in crude wastewater and
nal efﬂuent from a trickling ﬁlter WwTWs  (population equiv-
lent ∼105,000) in South-West England. Of the 90 compounds
tudied, 74% were found above the MQL  in crude wastew-
ter and 70% in ﬁnal efﬂuent (Table 3). In crude wastewa-
er, concentrations of >100 g L−1 for acetaminophen and 1,7
imethylxanthine were observed. In ﬁnal efﬂuent, EC concentra-
ions were expectedly lower. Nevertheless, several ECs (cetirizine,
larithromycin, acetaminophen, creatinine, metformin, ibupro-
en, naproxen and 4-benzophenone) remained at concentrations
1,000 ng L−1 (Table 3). Although sample numbers were limited,
ollection of corresponding grab samples to account for HRT gave
n insight into their removal by a trickling ﬁlter WwTWs.  These
re used extensively for wastewater treatment but receive less
ttention in comparison to other biological processes such as
ctivated sludge [24]. Several compounds which have not been
reviously studied in the UK were poorly removed. For example,
larithromycin, gliclazide, fexofenadine, irbesartan and cetirizine
ere all removed by <25% (Table 3). Interestingly metabolites of
arbamazepine (carbamazepine 10,11-epoxide and 10,11-dihydro-
0-hydroxycarbamazepine) and tramadol (N-desmethyltramadol)
ncreased in concentration during treatment. This observation has
reviously been observed for carbamazepine metabolites during
rickling ﬁlter treatment [33]. It is proposed that this is caused by
he transformation of other metabolites (e.g., glucuronides) or the. A 1431 (2016) 64–78 77
parent compound during wastewater treatment [33]. Nevertheless,
this requires more detailed investigation.
Water from an adjacent river (upstream of the wastew-
ater discharge point) was also collected. Here, 37% of ECs
investigated were above their respective MQL. Reported con-
centrations ranged from 1.8 ± 0.2 ng L−1 for sulfamethoxazole to
2318 ± 63 ng L−1 for metformin (Table 3). Metformin has been
previously reported in river water at mean concentrations of
∼3,000 ng L−1 [32]. This is attributed to its poor metabolism within
the body, its widespread usage resulting in high crude wastewa-
ter concentration and poor removal during biological wastewater
treatment (Table 3) [32]. Metabolites were also identiﬁed in
river water at notable concentrations. For example, mean con-
centrations of N-desmethyltramadol and O-desmethyltramadol
were 42.5 ± 7.1 ng L−1 and 95.0 ± 7.1 ng L−1, respectively. Their
presence at concentrations similar to the parent EC (tramadol
131.0 ± 21.2 ng L−1) demonstrates the importance of monitoring
metabolites as well as the parent EC for fate understanding and
the development of accurate environmental risk assessment.
Other than efﬂuent discharges, another source of EC contam-
ination in the environment is the application of digested sludge
(biosolids) to agricultural land. In digested sludge, 41 of the
63 extractable ECs (65%) were found above the MQL  (Table 3).
Of these compounds, 13 were determined to be at concentra-
tions >100 ng g−1 and considered to be signiﬁcant. These were
methylparaben, bisphenol-A, ibuprofen, propranolol, ﬂuoxetine,
norﬂuoxetine, sertraline, citalopram, desmethylcitalopram, carba-
mazepine, nicotine, morphine and EDDP. All antidepressants and
their metabolites studied were found above their respective MQL.
Furthermore, 5 of 8 antidepressants were determined at concen-
trations >100 ng g−1 highlighting the importance of studying this
chemical type in solid matrices. Bisphenol-A was found at the
highest concentration of 5800 ± 1,070 ng g−1. Due to the number
of compounds detected as well as the concentrations reported,
analysis of solid matrices should be considered for environmental
monitoring [1]. However, there are a lack of suitable analyti-
cal approaches reported in the literature for such matrices. This
method offers the opportunity to investigate the fate of a large
number of ECs in solid matrices.
4. Conclusion
A new multi-residue method was  developed for the deter-
mination of a high number of ECs in liquid (90) and solid (63)
environmental matrices. The sensitivity of the method was demon-
strated in real matrices whilst utilising low sample volumes/masses
(50 mL  for liquid samples and 0.5 g for solid samples). MQLs
achievable were <1.0 ng L−1 in wastewaters and river water, and
<1.0 ng g−1 in digested sludge. Application of the method revealed
several metabolites increased in concentration during wastewater
treatment demonstrating their analysis is necessary. Findings also
revealed analysis of liquid samples needs supported with solids
analysis. Thirteen ECs were found in digested sludge at concentra-
tions >100 ng g−1 and up to a maximum of 5800 ± 1,070 ng g−1 for
bisphenol-A. This method will be used to support monitoring stud-
ies to provide a greater understanding of the presence, fate and
ecological impact of ECs in wastewaters and the environment.
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